Breast Cancer, Endometrial Cancer, Ovarian Cancer, Prostate Cancer, Salivary Gland Cancer, Squamous Cell Carcinoma of the Cervix
Conditions
Keywords
Prostate cancer
Brief summary
The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer
Interventions
DRUGOPB-111001
Sponsors
Otsuka Novel Products GmbH
Study design
Allocation
NON_RANDOMIZED
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥ 18 years of age * Patients with prostate cancer that is recurrent or did not respond to previous hormone therapy and/or who have exhausted standard treatment options. For the dose escalation parts only: Patients who have exhausted standard treatment options with recurrent or refractory cancer (ovarian cancer, cervical squamous cell carcinoma, breast cancer, salivary gland cancer, endometrial cancer) * Histologically or cytologically documented diagnosis of cancer * Measurable disease according to RECIST Version 1.1 or for prostate cancer also evaluable disease according to Prostate Cancer Working Group 2 (PCWG2) eligibility criteria or for ovarian cancer also evaluable disease (non-measurable) according to Gynaecologic Cancer Intergroup (GCIG) criteria * Absolute neutrophil count ≥1.5 (1500/mm3) and platelets ≥100 × 109/L (without platelet transfusion within the last 4 weeks before first study drug administration), and haemoglobin ≥9 g/dL at Screening * Alanine aminotransferase and aspartate aminotransferase ≤2.5 × the upper limit of normal (ULN), Total bilirubin ≤1.5 × ULN (exception: patients with liver metastasis are allowed to have aspartate aminotransferase ≤5 × ULN and alanine aminotransferase ≤5 × ULN) at screening * Albumin ≥26 g/L at Screening
Exclusion criteria
* Concurrent prior treatment-related toxicity of Grade 2 or higher. Exception: any toxicity that is in the view of the investigator not a clinically significant safety risk for Investigational medicinal product (IMP) administration. * Previous treatment with cytotoxic chemotherapy or other anticancer therapy within 4 weeks before the first dosing with study drug (at least 6 weeks for mitoxantrone, nitrosurea, and bicalutamide). * Treatment with systemic glucocorticosteroids of more than a 2 mg dexamethasone equivalent per day or in cases of treatment with ≤2 mg dexamethasone equivalent per day: 1. Dosing was changed within 6 weeks before Screening or 2. The patient's cancer is responding to glucocorticosteroid intake * Radiation therapy within 4 weeks prior to the first dosing with IMP. * Treatment with a systemic IMP in a clinical trial within 28 days before the Screening Visit. * Current or past history of clinically significant gastrointestinal disease or major gastrointestinal surgery, malabsorption syndrome, or other conditions that could interfere with enteral absorption. * Concurrent clinically significant unrelated systemic illness (e.g., serious infection) or significant pulmonary, hepatic, or other organ dysfunction that would compromise the patient's ability to tolerate study treatment or would likely interfere with study procedures or results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum tolerated dose / Recommended Phase 2 dose; Tolerability | after 2 or 6 weeks depending on study part; continously |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic parameters for OPB-111001 and its metabolites | repeatedly until end of study (average of 3 months assumed) | Frequent sampling during Cycle 1 to 3, D1 only from Cycle 4 onwards |
| Assessment of antitumor activity as defined by Response Evaluation Criteria in Solid Tumours (RECIST) | repeatedly every 8th week until end of study (average of 3 months assumed) | — |
| Prostate-specific antigen (PSA) response in patients with prostate cancer | repeatedly (Cycle 1 to 3 on Day 1, then every 4th week) until end of study (average of 3 months assumed) | — |
| Cancer antigen 125 (CA 125) response in patients with ovarian cancer | repeatedly (Cycle 1 to 3 on Day 1, then every 4th week) until end of study (average of 3 months assumed) | — |
| Time to treatment failure | At end of study (after average of 3 months assumed) | — |
Countries
United Kingdom
Outcome results
None listed